Intranasal versus intravenous administration of midazolam to children undergoing small bowel biopsy

Acta Paediatr. 1995 Dec;84(12):1429-31. doi: 10.1111/j.1651-2227.1995.tb13582.x.


Sixty-three children under the age of 9 years were randomized to receive intravenous (group A, n = 33) or intranasal (group B, n = 30) midazolam as sedation for small bowel biopsy. Mean doses of midazolam given to produce adequate sedation were 0.31 mg (kg body weight)-1 in group A and 0.34 mg (kg body weight)-1 in group B (NS). Four children in group A and 10 children in group B required additional doses to maintain adequate sedation throughout the biopsy procedure (p < 0.05). There was no significant difference between the groups regarding the median procedure time (7 min in group A, 8.5 min in group B) or median fluoroscopy time (5 s in group A, 4 s in group B). All children in group B showed signs of discomfort from the nose when given midazolam intranasally. In conclusion, this study indicates that intravenous administration of midazolam is preferable to the intranasal route.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Intranasal
  • Biopsy*
  • Child
  • Child, Preschool
  • Conscious Sedation*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Infant
  • Infusions, Intravenous
  • Intestinal Mucosa / pathology*
  • Intestine, Small / pathology*
  • Male
  • Midazolam*


  • Midazolam